CRISPR: Challenges to South African biotechnology law by Pillay, S & Thaldar, D.W.
November 2018, Vol. 11, No. 2    SAJBL     89
ARTICLE
Gene editing is a technology that enables changes to an organism’s 
DNA by adding, removing or altering genes so as to change gene 
expression. However, unlike genetic modification, which introduces 
foreign DNA (transgenes) into an organism, gene editing does not 
introduce transgenes – instead, the technology is limited to the 
DNA naturally present in the organism’s gene pool (this point will 
be clarified further below). The new ‘tool’ that has proved highly 
successful and reliable to accomplish gene editing is CRISPR-Cas9. 
The discovery of CRISPR-Cas9 in bacteria, and its novel application 
in plant and animal cells, has been hailed as revolutionary.[1] While 
CRISPR-Cas9 is being explored, analogous systems are also being 
discovered – such as CRISPR-Cas12a.[2] These genome-editing tools 
are showing potential not just to correct gene defects, but also to 
enhance the phenotype. However, given the expanding possibilities 
offered by this technology, the legal, ethical and social issues are also 
becoming clearer and more pressing.[1] 
Currently, there is international debate on how CRISPR-Cas9 should 
be regulated in applicable industries. Actors involved recognise the 
need to advance this technology to maximise benefits to society, 
but also the need to apply caution so as to protect public and 
environmental health.[3] Central to these debates is the fact that 
CRISPR-Cas9 is a relatively nascent technology, the potential of which 
to impact on human, animal and environmental health cannot be 
determined with perfect clarity. This echoes the sentiments in the 
debate on genetically modified organisms (GMOs). However, CRISPR-
Cas9 is not limited to agricultural biotechnology; it also extends to 
other areas, such as human biotechnology. In this latter context, the 
discovery of CRISPR-Cas9 has reignited the global ethical debate on 
human genetic engineering. 
In this article, we provide an overview of CRISPR-Cas9 technology, 
and present key areas of concern in the South African (SA) legal 
context – pertaining to agriculture, human gene therapy, patenting 
and consumer protection. Our intention is to draw attention to 
potential ethical and legal problems in order to stimulate academic 
debate – not to suggest substantive solutions. 
The CRISPR revolution
The manipulation of the DNA in genes has been possible for decades. 
Technologies have been invented since the DNA helical structure 
was first understood, but site-specific modifications in genomes 
were still unachievable.[4] In recent years, site-specific technologies 
such as zinc finger nucleases (ZFNs) and transcription activator-like 
effector nucleases (TALENs) were created, but had shortcomings that 
rendered them unfeasible for use in live organisms.[4] CRISPR promises 
to overcome these shortcomings by providing improved specificity, 
versatility, efficiency and accessibility.[5]
The CRISPR-Cas system is found in the adaptive bacterial immune 
system, and acts like molecular scissors.[4] A variant – CRISPR-Cas9 – 
was applied successfully to the eukaryotic system by Doudna and 
Charpentier.[4] Through this novel application of a simple bacterial 
genome-editing system to a eukaryotic cell, scientists realised the 
value of CRISPR-Cas variants in targeting, marking, editing, modifying 
and regulating the genome with greater ease, precision, efficiency 
and cost-effectiveness.[4]
Agri-biotechnology 
In agriculture, CRISPR-Cas technology has the potential to improve 
crop quality and yield, and to introduce disease resistance[6] – for 
example, genome-edited mushrooms that brown slower than other 
mushrooms, so increasing their shelf-life.[7] GMOs aimed to achieve 
the same goals, but required the introduction of foreign DNA, 
resulting in transgenes. A main point of contention with GMOs, then, 
was how to prevent the cross-pollination of genetically engineered 
plants with their relative plants in the wild.[1] As such, regulations in 
the agricultural use of GMOs focused on preventing GMO release in 
the environment or market in ways that may impact wild types. 
The Genetically Modified Organisms Act No. 15 of 1997 (GMO 
Act) outlines the requirements of an application to pursue GMOs. 
These requirements include scientifically based risk assessment, 
socioeconomic considerations, environmental impact and risk 
management measures.[8] Other SA acts concerned with the 
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mitigation of the environmental impact of GMOs include the National 
Environmental Management Act No. 107 of 1998, and the National 
Environmental Management Biodiversity Act No. 10 of 2004. 
These statutes focus on GMOs, with the reason for stringently 
regulating GMOs, as seen in the Cartagena Protocol on Biosafety in 
2003, being that GMOs incorporate foreign DNA (transgenes), and the 
view advanced by some that the long-term effect on the environment 
and consumer health of transgenic organisms is unknown. However, 
genome editing does not require the incorporation of foreign DNA; 
it is a process of mutagenesis, not transgenesis. To clarify this point 
further, genetically edited organisms do not possess DNA that 
exists outside their gene pool, where gene pool refers to the genes 
present within a population of naturally interbreeding species. By 
this definition, gene editing is seen almost as an enhanced natural 
breeding process; that is, the DNA does not undergo any changes 
that normal reproductive processes cannot hypothetically achieve. 
This contrasts with gene modification, wherein DNA that does not 
naturally exist in the gene pool is added to achieve a certain trait. In 
this scenario, under conventional reproduction, these foreign genes 
would not typically enter the gene pool of the organism, and may 
confer traits that are atypical.
This is a pivotal fact to consider when answering the question that 
is being raised on whether these regulations on GMOs can be applied 
to genome-edited organisms. Some maintain that genome editing 
using CRISPR-Cas technology does not pose any greater threat than 
conventional breeding practices, as there is no introduction of foreign 
DNA into the organism.[9] An example of this is the emerging policy 
in the USA that the Food and Drug Administration (FDA) does not 
regulate CRISPR-Cas technology end-products, such as genetically 
edited mushrooms[7] and maize,[10] as these do not contain DNA 
from plant pests such as viruses and bacteria, and are therefore not 
transgenic.
In Europe, the issue of whether genome-edited organisms would 
be regulated under current GMO legislation[11] was brought to the 
European Court of Justice by a French agricultural union of small-
scale farmers, in the case of Confédération Paysanne and Others v 
Premier Ministre and Ministre de l’Agriculture, de l’Agroalimentaire 
et de la Forêt C-528/16. The agricultural union argued that although 
mutagenesis is excluded from regulation, more modern methods 
of mutagenesis – genomic editing – are threatening the health 
of humans and the environment and should not be exempt from 
regulation. In 2016, the French government asked the European 
Court of Justice to provide clarity on the interpretation of the 
directive that regulated GMOs – essentially asking whether products 
of new methods of genome editing fell under the mutagenesis 
exemption. Before deciding a matter, the European Court of Justice 
can request an independent legal opinion from its panel of Advocates 
General. Such opinions are influential in the court’s eventual decision, 
and are followed in about two-thirds of decisions. In this case, Adv. 
Gen. Michal Bobek was requested to provide an opinion, and he filed 
his opinion in January 2018.[12] He opines that products created using 
mutagenesis techniques fall under the ambit of the mutagenesis 
exemption, except in certain cases – such as where recombinant 
nucleic acid molecules are used, or where DNA that does not 
occur naturally is introduced.[12] This means that genomic editing 
may, in many cases, fall outside the ambit of the European GMO 
regulatory framework. However, Adv. Gen. Bobek points out that 
individual member states still have the authority to enforce their own 
regulations of gene-edited products and processes.[12] The decision 
by the European Court of Justice, as of July 2018, is that genetically 
edited plants are subject to the same laws as GMOs. 
In SA, the GMO Act’s definition of a GMO is ‘an organism the 
genes or genetic material of which has been modified in a way that 
does not occur naturally through mating or natural recombination 
or both’.[8] This definition clearly mirrors GMO definitions in the 
USA, European Union and elsewhere. As such, as evidenced by 
our discussion of foreign jurisdictions, it is conceivable that SA 
regulators and courts would view genome-edited organisms as in 
some instances falling within and in some instances falling outside 
this definition – depending on the exact nature of the genome 
editing that took place. However, lobby groups are already taking 
positions: the Africa Centre for Biodiversity calls for a strict ban on 
genome-edited techniques until the ‘risks’ of the products can be 
assessed.[13] Though the report distinguishes between the method 
used to create GMOs and that of mutagenesis, the report raises two 
overall concerns that have been mentioned above: (i) mutagenesis as 
a technique cannot be disregarded in terms of safety and scientific 
validity; and (ii) the products of genome editing, though acquired 
by mutagenesis, may still be classified as GMOs. Lobbyists also argue 
that the use of recombinant DNA still introduces foreign DNA to 
the organism. The Africa Centre for Biodiversity expands on other 
existing concerns regarding the scientific feasibility of mutagenesis, 
claiming that around ‘70% of mutations lead to detrimental and 
not beneficial effects’.[13] However, such sweeping statements seem 
to ignore the evolution of mutagenesis techniques from those that 
caused widespread and unspecific mutations, such as irradiation, 
to that of CRISPR, which promises better specificity. Essentially, the 
Africa Centre for Biodiversity echoes the question raised by the 
international community – do current GMO regulations pertain to 
genome editing? Clearly, legal certainty is needed. If the question is 
answered similarly to the way it has been answered in the USA, and 
in the opinion of Adv. Gen. Bobek, SA may also consider genome-
editing-specific legislation to address the regulatory gap.
Gene editing in human somatic cells, 
germlines and embryos
The current literature focuses largely on the scientific risks and 
benefits, and also the ethics, of altering somatic cells vis-à-vis germline 
and embryonic cells.[14] 
Somatic cells
The main question raised in the alteration of somatic cells is whether 
scientists can accurately predict how editing a specific set of genes 
can affect the rest of the genome, and whether possible adverse 
effects and risks can be sufficiently understood. However, none of 
these questions can be fully answered without conducting extensive 
research. In 2016, the USA approved the first protocol for gene 
therapy that uses CRISPR-Cas technology.[5] The first phase I clinical 
trial of using CRISPR-modified lymphocytes against lung cancer in 
humans is imminent in China.[5] 
While the current safety of somatic-cell gene therapy is still being 
investigated, it is relatively uncontroversial ethically, and will be 
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regulated as ‘medicine’ by the Medicines and Related Substances 
Act No. 101 of 1965. Not all uses of somatic-cell gene editing will 
necessarily be therapy – some conceivable uses of somatic cell 
gene editing can be viewed as non-therapeutic, or ‘enhancement’. 
Although the therapy-enhancement distinction is popular among 
bioethicists to draw the line between acceptable and non-acceptable 
uses of genetic technology in humans, there is no consensus on this 
issue. In fact, there are examples in conventional medicine where 
medical technology is used for non-therapeutic purposes. Cosmetic 
surgery is perhaps the most apparent example. Other examples may 
include the use of concentration-enhancing psychiatric medicines 
that were intended to treat conditions such as ADHD by people 
who do not have ADHD or a similar condition. How one perceives 
enhancements will depend on how one interprets and balances 
norms such as autonomy and fairness. 
Germline and embryonic cells
Germline and embryonic cells are a more contentious area of gene 
therapy. Germline cells develop into the reproductive cells of an 
individual, and alteration of these cells is heritable; that is, the alteration 
will be passed onto the offspring resulting from those reproductive 
cells. The key issue here is similar to that of somatic cells – that not all 
the risks to the rest of the genome are known – but now it also concerns 
the genomes of the offspring. Embryonic-cell gene editing shares this 
concern, but there is an added dimension of whether genome-edited 
embryos can be safely implanted in the uterus.
The United Nations Educational, Scientific and Cultural Organization 
(UNESCO) has taken a conservative stance, calling for a temporary 
ban on any use of germline gene editing.[3] The US National Academy 
of Sciences and the National Academy of Medicine released a report 
entitled Human Genome Editing: Science, Ethics, and Governance, 
in which a slightly more flexible approach is adopted that allows 
for clinical trials of germline gene editing if ten criteria are met.[15] 
Internationally, according to a survey of 39 countries – including 
the UK, USA, China and SA – conducted by Araki and Ishii,[16] there is 
dissidence regarding the ban on human germline editing. China does 
not have a legal ban, but rather a guideline-based ban on germline 
editing,[16] and takes the Confucian view that because the status of 
human beings is only acquired upon birth, and not before, the use of 
embryos for research is permissible.[17] 
It is therefore unsurprising that the first study reporting CRISPR 
genetic editing of human embryos was conducted by a research 
team in China. Liang et al.[18] used non-viable embryos with a triploid 
set of chromosomes to investigate CRISPR-Cas9-mediated gene 
editing.[18] The tool effectively cleaved the desired HBB β-globin gene; 
however, the efficiency of the gene repair after cleavage was low. 
Furthermore, there was also off-target gene cleavage and mutations. 
While this is not scientifically feasible for progression to clinical trials, 
it is a critical first step in identifying the challenges when using 
CRISPR technology in embryos.[18] Indeed, this research was the focus 
area of the 2015 International Summit on Human Gene Editing held 
in Washington DC by the US National Academy of Sciences, the US 
National Academy of Medicine, the Royal Society, and the Chinese 
Academy of Sciences.[17] The final position was that the research 
should not be condemned, and though there was disagreement in 
the scientific community about the extent of applying gene editing 
to embryos, some countries have recognised the value of allowing 
research in germline editing.[17] 
Though current UK legislation, namely the Human Embryology and 
Fertilisation Act, prohibits the implantation of genetically modified 
embryos,[1] there is no legal ban on germline editing,[16] and research 
into this area of genetic editing of the germline and embryos 
may continue as long as it is licensed by the Human Fertilisation 
and Embryology Authority.[6] The USA has taken a more cautious 
approach, with the FDA and National Institutes of Health placing a 
temporary moratorium on germline gene editing until sufficient risk 
and safety assessments have been conducted.[16] Other countries such 
as Sweden and Canada have banned germline editing, maintaining 
that this practice should be banned because it may affect the 
development of the embryo. As Araki and Ishii[16] point out, whether 
this reasoning will still stand if gene correction leads to normal 
development of the embryo, is uncertain.
SA’s regulatory regime regarding germline genome editing is 
perceived as ambiguous.[16] This is not surprising, as the National 
Health Act No. 61 of 2003 bans ‘reproductive cloning’ of humans, 
and appears to define ‘reproductive cloning’ so broadly as to possibly 
include any germline genome editing. Given this strange definition, 
legal certainty is compromised.
Patenting CRISPR technology 
Despite the ongoing patent litigation, the University of California and 
the Broad Institute, the Massachusetts Institute of Technology (MIT) 
and Harvard University have all proceeded to grant broad exclusive 
licences to use their respective CRISPR technologies commercially;[19] 
the Broad Institute, MIT and Harvard state that academic and non-
profit use shall not require licences.[20] For example, the Broad Institute 
employs an ‘inclusive innovation model’ wherein the surrogate 
company Editas is a primary licensee of exclusive licences, but after 
an initial period, other companies may be granted licences for the 
CRISPR technology.[20] Sherkow[19] voices the concern that this may 
prevent other smaller companies from innovating using CRISPR-Cas9 
technology, and suggests that co-operative patent licensing should 
be encouraged, as opposed to exclusivity and patenting thickets. The 
University of California and the Broad Institute have announced that 
they are working on a patent pool and other mechanisms to enhance 
access to CRISPR technology, but this requires foundational patent 
owners,[21] which include the company Šikšnys and other agricultural 
companies such as Monsanto, DuPont Pioneer, Caribou Biosciences, 
and ERS Genomics.[19]
Apart from the issue of access to technology, there is also the 
issue of whether down-the-line inventions using CRISPR technology 
would even be patentable. Sherkow[19] questions whether there is 
any non-obvious application of CRISPR-Cas9, with obvious negative 
consequences for patentability.[19] The process itself has already been 
patented, and it may be possible that future patents will include the 
use of the technique in claims to the genome-edited end products. 
However, what is debatable is: (i) whether these gene-edited end 
products are patentable subject matter, as they may be regarded 
as products of nature,[22] a debate predating genome editing; (ii) 
whether these gene-edited end products, if they are homologous 
to corrected genes present in a normal healthy population, fulfil the 
novelty criterion of patentability;[22] and (iii) whether the production 
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of the edited genes introduces a non-obvious step that is required for 
patent eligibility.[22] 
A search on ‘CRISPR’ through the SA patent database shows that 
there is one CRISPR patent granted in SA – to a Swiss company CRISPR 
Therapeutics. Another patent application that was filed by MIT, the 
Broad Institute and the University of Iowa has been accepted, but is 
not yet granted. A further 12 patent applications by various institutes 
or companies in the USA are pending in the SA Patent Office (SAPO). 
It should be remembered that SAPO does not examine the substance 
of patent claims, as the USA and the EU do – however, SAPO aims to 
move in this direction. As such, the fact that a certain patent has been 
granted in SA does not necessarily reflect on the legal tenability of the 
patent’s claims. In the current system, this can only be tested in court. 
Given the fact that SAPO intends to move towards an examining 
system, it would assist with legal certainty if SAPO could articulate 
a position regarding the patentability of CRISPR technology and 
genome-edited end products in SA. 
Regulating the consumer market
Another issue involving the protection and promotion of human 
health is the marketing and labelling of genome-edited foods.[1] In 
SA, the Consumer Protection Act No. 68 of 2008, which defines GMOs 
as defined in section 1 of the GMO Act, provides that GMO content 
of certain categories be noted on food labels.[23] If gene-edited foods 
are not considered as GMOs, this may avoid the labelling regime, and 
may also avoid possible rejections by some sectors of the consumer 
public.[24]
Conclusion
CRISPR technology affects a whole range of ethical and legal fronts. 
What should be clear from our discussion is that SA faces challenges 
on all of these fronts, and requires greater legal clarity regarding the 
regulation of this new technology. By identifying these fronts, we 
hope to stimulate academic analysis in the SA context. In summary, 
such academic analysis should aim at the following most pertinent 
areas where legal clarity is most required: (1) Whether CRISPR-Cas9 
falls within the ambit of the GMO Act’s definition of a GMO, and if 
not, whether there are convincing public policy reasons for amending 
the Act to include gene-edited foods within its regulatory ambit. 
(2a) Whether there is an ethical limit to the application of genome 
editing in humans, and if so, how such limit should be regulated 
in law. (2b) Whether human germline editing qua specific kind of 
genome editing in humans should be legally banned, regulated, 
or unregulated, and if regulated, the conditions and oversight 
mechanisms should be given good thought. (3) In the context of 
patenting, where there are overlapping claims, which should prevail, 
and given the breadth of the prevailing claims, whether there is space 
for patenting genome-edited end products in SA. (4) Lastly, having 
regard to the answer to point (1) above, whether gene-edited foods 
should require labelling similar to the current GMO labelling. Not 
one of these areas has an easy or obvious answer – each one calls for 
in-depth academic analysis in the SA context. Science itself cannot 
tell us what to do. We introduce norms to facts. 
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